Studies related to Anxiety and Coenzyme Q10

Can Coenzyme Q10 Improve Clinical And Molecular Parameters In Fibromyalgia?

Effect Decrease
Values Figure 2.
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 20
Sex Both Genders
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 20 participants with fibromyalgia were allocated to take 300 mg daily of coenzyme q10 or placebo for 40 days.

The primary outcome was the change in fibromyalgia symptoms as assessed by FIQ (fibromyalgia impact questionnaire), and there was a considerable, statistically significant reduction compared with placebo. The statistically significant reduction held for pain, fatigue, morning tiredness, stiffness, anxiety, and depression scores. Tenderness also improved significantly, while sleep quality didn't see a greater improvement than placebo. Overall rating of condition severity with a visual analog scale also suggested a significant improvement. Gene expression of IL-6, IL-8, and TNF, was reduced significantly, while PGC-1a, TFAM, NRF1, SOD1, and SOD2 increased.

Full details on all 2 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.